Last reviewed · How we verify
Hydromorphone PCA
At a glance
| Generic name | Hydromorphone PCA |
|---|---|
| Also known as | Dilaudid |
| Sponsor | M.D. Anderson Cancer Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Spinal Anesthesia For Enhanced Recovery After Liver Surgery (NA)
- Methadone as an Alternative Treatment for Children Underdoing HSCT (PHASE3)
- Evaluating Pain Control Strategies in Postpartum Patients on Opioid Use Disorder Medications. (EARLY_PHASE1)
- Multimodal Analgesia Effect on Post Surgical Patient (PHASE4)
- Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy (PHASE2)
- IV vs Epidural Opioids + Epidural Local Anesthetic for Laparotomy Analgesia (PHASE2, PHASE3)
- IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration (PHASE3)
- Comparison of the Effects of Hydromorphone and Nalbuphine Patient Controlled Analgesia in Postoperative Pain After Cesarean Section
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydromorphone PCA CI brief — competitive landscape report
- Hydromorphone PCA updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI